Morgan Stanley analyst Maxwell Skor assumed coverage of Insmed (INSM) with an Overweight rating and $90 price target The firm views Insmed as well-positioned to drive meaningful value creation this year through the potential approval and launch in bronchiectasis, as well as data readouts from TPIP and brensocatib, says the analyst, who also notes that Q4 marked Arikayce’s “highest quarterly sales ever.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Strategic Growth and Promising Pipeline Drive Buy Rating
- Insmed price target raised to $110 from $105 at UBS
- Block upgraded, Domino’s downgraded: Wall Street’s top analyst calls
- RBC Capital starts Insmed at Outperform on brensocatib launch momentum
- Insmed initiated with an Outperform at RBC Capital